Alpha 2.0
Login Register
» Articles » PMID: 21792563

Differences in the Consumption Rates and Regulatory Barriers to the Accessibility of Strong Opioid Analgesics in Israel and St. Petersburg

Overview
Journal Eur J Clin Pharmacol
Specialty Pharmacology
Date 2011 Jul 28
PMID 21792563
Citations 5
Authors
Alexander M Ponizovsky
Michael V Pchelintsev
Eli Marom
Edwin E Zvartau
Affiliations
Soon will be listed here.
Abstract

Objective: To compare trends in opioid consumption in Israel and St. Petersburg/Russia (morphine, oxycodone, pethidine, fentanyl, methadone, buprenorphine, trimeperidine, and papaveretum) over the period 2000-2008, and to describe the regulatory barriers to their accessibility as an exploratory variable for between-country differences.

Methods: Data were drawn from the databases maintained by the Israel Ministry of Health's Pharmaceutical Administration and the St. Petersburg Central Pharmaceutical Reserve. The data were converted into a defined daily dose (DDD)/1,000 inhabitants/day. Regulation was evaluated according to the WHO guidelines for the assessment of national opioid regulation.

Results: The opioid consumption rates in Israel were substantially higher than those in St. Petersburg. The excess in DDD/1,000 inhabitants/day was for fentanyl +0.287 in 2000 and +1.206 in 2008, for morphine +0.245 in 2000 and +0.122 in 2008, and for pethidine/trimeperidine +0.035 in 2000 and +0.007 in 2008. Oxycodone consumption increased in Israel from 0.31 DDD/1,000 inhabitants/day in 2000 to 0.46 DDD/1,000 inhabitants/day in 2008, whereas this analgesic is not available in St. Petersburg. Methadone and buprenorphine consumption rose in Israel, whereas these drugs are not available in Russia. Conversely, omnopon consumption decreased in St. Petersburg from 0.0206 DDD/1,000 inhabitants/day in 2000 to 0.00304 DDD/1,000 inhabitants/day in 2008, whereas the compound is not available in Israel. St. Petersburg differs from Israel with less opioid formulary availability and greater regulatory restrictions.

Conclusion: The results suggest that strong opioid analgesics consumption rates in St. Petersburg yield those in Israel, and that the between-countries differences in opioid formularies availability and legal and regulatory barriers to opioids accessibility are responsible for the consumption discrepancies.

Citing Articles

Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan.

Wu T, Hsu C, Sun W, Chen H, Lin C, Shao Y Lancet Reg Health West Pac. 2021; 16:100255.

PMID: 34590061 PMC: 8406032. DOI: 10.1016/j.lanwpc.2021.100255.

Analgesic Medicine Utilization in Older People in New Zealand from 2005 to 2013.

Nishtala P, Oh S, Kim D, Chun N, Kamis S, Kiu K Drugs Real World Outcomes. 2016; 2(2):177-185.

PMID: 27747769 PMC: 4883194. DOI: 10.1007/s40801-015-0026-5.

Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia.

Tsui J, Cheng D, Coleman S, Lira M, Blokhina E, Bridden C Drug Alcohol Depend. 2014; 144:87-92.

PMID: 25220898 PMC: 4252482. DOI: 10.1016/j.drugalcdep.2014.08.013.

Changes in trends and pattern of strong opioid prescribing in primary care.

Zin C, Chen L, Knaggs R Eur J Pain. 2014; 18(9):1343-51.

PMID: 24756859 PMC: 4238849. DOI: 10.1002/j.1532-2149.2014.496.x.

Pain is associated with heroin use over time in HIV-infected Russian drinkers.

Tsui J, Cheng D, Coleman S, Blokhina E, Bridden C, Krupitsky E Addiction. 2013; 108(10):1779-87.

PMID: 23773361 PMC: 4012755. DOI: 10.1111/add.12274.

References
1.
Hamunen K, Paakkari P, Kalso E . Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2008; 13(9):954-62. DOI: 10.1016/j.ejpain.2008.11.006. View
2.
Cicero T, Inciardi J, Surratt H . Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug Alcohol Depend. 2007; 91(2-3):115-20. DOI: 10.1016/j.drugalcdep.2007.05.008. View
3.
Sinatra R . Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain. J Am Board Fam Med. 2006; 19(2):165-77. DOI: 10.3122/jabfm.19.2.165. View
4.
de Leon-Casasola O . Current developments in opioid therapy for management of cancer pain. Clin J Pain. 2008; 24 Suppl 10:S3-7. DOI: 10.1097/AJP.0b013e31816b589f. View
5.
Spiller H, Lorenz D, Bailey E, Dart R . Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis. 2009; 28(2):130-6. DOI: 10.1080/10550880902772431. View